A Short Appraisal of polylactic-co-glycolic Acid Based Polymer Nanotechnology for Colon Cancer: Recent Advances and Literature Evidences

Abstract

The currently available formulations provided non-targeted treatment of colon cancer, the deadliest cancer variant. Due to biopharmaceutical hindrances, the majority of the drugs are unable to reach the target site. Polylactic-co-glycolic acid (PLGA) is one of the versatile polymers in cancer treatment, diagnostics and theranostics. The unique mechanism of surface modifications in PLGA properties in colon cancer has been a keen interest to be used in different nanoparticles for improving biopharmaceutical attributes. The ongoing use of these smart nano-carriers has allowed targeted delivery of several active components on a wide scale. The main goal of this review is to compile information on PLGA-based nanocarriers which possess several desirable properties for drug delivery applications, including biocompatibility, biodegradability and tunable drug-release kinetics.

Keywords:

• colon cancer
• nanotechnology
• PLGA
• target delivery
• theranostics

Author contributions

D Singh, BD Kurmi and A Vashishat conceptualized the idea. A Vashishat, A Singh and GD Gupta prepared the draft. D Singh and BD Kurmi approved for final approval and submitted the initial version to the journal.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.